112623-19-5Relevant academic research and scientific papers
FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE
-
Page/Page column 41, (2020/05/06)
The present invention provides flavone derivatives having the general formula (I) which are useful for the treatment of Hepatitis B Virus infection (HBV). The compounds act as cccDNA (covalently closed circular DMA) inhibitors.
FUSED HETEROCYCLIC OR CARBOCYCLIC COMPOUNDS CARRYING A SUBSTITUTED CYCLOALIPHATIC RADICAL AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES
-
Page/Page column 76-77, (2016/03/19)
The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula (I) wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compoun
ANTIBACTERIAL AGENTS
-
Page/Page column 106, (2014/10/18)
Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts and esters thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.
ANTIDIABETIC TRICYCLIC COMPOUNDS
-
Page/Page column 132, (2014/02/16)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
ANTIDIABETIC TRICYCLIC COMPOUNDS
-
Page/Page column 118, (2014/02/16)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
-
Page/Page column 97, (2015/05/06)
The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them
-
, (2008/06/13)
The invention is directed to cyclobutane derivatives represented by general formula (I): wherein A represents a hydrogen atom, a hydroxy group, an azido group or an amino group; and B represents a purine residue or a pyrimidine residue. The cyclobutane de
2-Oxabicyclohexane and 2-Oxabicyclohex-5-yl Derivatives
Kirmse, Wolfgang,Mrotzeck, Uwe
, p. 1013 - 1016 (2007/10/02)
2-Oxabicyclohexane (1) has been obtained by cyclization of 3-hydroxycyclobutanemethanol (9) while ethyl 2-oxabicyclohexane-endo-5-carboxylate (19) is accessible from ethyl 3-(2-propenyloxy)propenoate (18) by intramolecular photocycloaddition
